ArticleGeneral thoracic and cardiovascular surgery2026
Clinical predictors of pathological response after immunotherapy in salvage surgery for non-small cell lung cancer: a supplementary analysis of the CReGYT-05 immune checkpoint inhibitor-salvage study.
Article in General thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Revisiting "Organ-specific recurrence patterns after lung cancer resection: methodological and biological perspectives".General thoracic and cardiovascular surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRadiological responses based on tumor size reduction are often unreliable after immune checkpoint inhibitor (ICI) therapy for non-small cell lung cancer (NSCLC), particularly in salvage surgery. The aim of this study was to evaluate the association between MPR and prognosis, and to determine whether changes in metabolic response on positron emission tomography/computed tomography (PET/CT) and tumor marker levels can identify patients who achieve a major pathological response (MPR) despite residual disease.
methodsThis multicenter retrospective study (CReGYT-05 ICI-Salvage study) included patients with NSCLC who underwent salvage lung resection after ICI therapy at 14 institutions in Japan. Metabolic response was evaluated by changes in maximum standardized uptake value (SUVmax). Pathological response was classified as MPR (≦10% viable tumor cells). Associations among metabolic response, tumor markers, pathological response, and survival were analyzed.
resultsAmong 31 evaluable patients, 11 (35%) achieved MPR. Patients with MPR had improved 5-year overall survival compared with those without MPR (100% vs. 40.3%; p = 0.017). In univariate analysis, serum CEA decreased (odds ratio [OR], 16.000; 95% confidence interval [CI], 2.105-343.167; p = 0.005), SUVmax decreased ≧60% (OR, 25.000; 95% CI, 2.441-661.493; p = 0.005), and cStage IV (OR, 0.125; 95% CI, 0.020-0.608; p = 0.009) were suggested to be associated with MPR.
conclusionsRadiologic response alone is insufficient to identify major pathological responders after ICI therapy. PET/CT metabolic response combined with tumor marker changes provides clinically meaningful information for selecting candidates for salvage surgery.
Indexed as
Identifiers
42176153What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.